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Stem cell therapy appears to be promising for restoring damaged or irreparable lung tissue. However, establishing a simple and
reproducible protocol for preparing lung progenitor populations is difficult because the molecular basis for alveolar epithelial cell
differentiation is not fully understood.We investigated an in vitro system to analyze the regulatory mechanisms of alveolus-specific
gene expression using a human alveolar epithelial type II (ATII) cell line, A549. After cloning A549 subpopulations, each clone was
classified into five groups according to cellmorphology andmarker gene expression. Two clones (B7 andH12)were further analyzed.
Under serum-free culture conditions, surfactant protein C (SPC), an ATII marker, was upregulated in both H12 and B7. Aquaporin
5 (AQP5), an ATI marker, was upregulated in H12 and significantly induced in B7. When the RAS/MAPK pathway was inhibited,
SPC and thyroid transcription factor-1 (TTF-1) expression levels were enhanced. After treatment with dexamethasone (DEX), 8-
bromoadenosine 3󸀠5󸀠-cyclic monophosphate (8-Br-cAMP), 3-isobutyl-1-methylxanthine (IBMX), and keratinocyte growth factor
(KGF), surfactant protein B and TTF-1 expression levels were enhanced. We found that A549-derived clones have plasticity in gene
expression of alveolar epithelial differentiation markers and could be useful in studying ATII maintenance and differentiation.
1. Introduction
Lung diseases such as chronic obstructive pulmonary disease
and idiopathic pulmonary fibrosis can be life threatening.
Until now, lung transplantation has been the treatment
of choice for the severe cases [1]. However, lung trans-
plantation is associated with several problems, including
issues with histocompatibility and a shortage of donors.
Therefore, regenerative medicine of the lungs using stem
cells is attracting a lot of attention as a promising therapy
[2, 3]. Recently, embryonic stem cells (ESCs) and induced
pluripotent stem cells (iPSCs) have been used to study the
possible regeneration of alveolar epithelial type (AT) cells
[4, 5]. Differentiation into AT cells from ESCs and iPSCs still
needs to pass through the several developmental stages, and
the regulation of this developmental process remains unclear.
Thus, it is required to establish a simple and reproducible
model system to understand the molecular basis of the
differentiation of divergent progenitor populations in the
human lung and to further develop lung regenerative therapy.
Lung alveoli, which are essential for respiratory function,
are composed of two types of alveolar epithelial cells, that
is, type I (ATI) and type II (ATII). ATI cells are flat cells
that cover 95% of alveoli, and they are involved in the
exchange oxygen and carbon dioxide [6, 7]. These cells
express specific differentiation markers, such as aquaporin 5
(AQP5 [8, 9]), caveolin-1 [10], and the receptor for advanced
glycation end products [11]. ATII cells are cuboidal cells
and produce surfactant, which consists of proteins such as
surfactant proteins A, B, C, and D (SPA, SPB, SPC, and
SPD), and phospholipids. These surfactants are essential for
maintenance of alveoli and host defense [12–14]. SPA, SPB,
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and SPD are synthesized in both Clara cells and ATII cells.
SPC is synthesized only in ATII cells and, therefore, is a
specific marker for ATII cells [15]. The cell-type-specific
expressions of SPB and SPC in Clara and ATII cells are
required for lung respiratory function [16, 17]. Both gene
expressions are regulated by thyroid transcription factor 1
(TTF-1) during lung development [18–20]. ATII cells have
the stem cell-like properties of self-renewal, proliferation,
and differentiation into ATI cells following injury [21–26].
Therefore, it is quite important to prepare a simple and
reproducible ATII cell model system and establish a protocol
to control the differentiation into ATI cells.
In this study,we used a humannon-small cell lung cancer-
derived cell line, A549, to explore the possibility whether
A549 cells are suitable for investigating the regulation of
gene expression of differentiationmarkers. A549 cells are well
studied and known to have both K-RAS mutations (G12S)
and epidermal growth factor receptor (EGFR) gene amplifi-
cation [27–29]. A549 cells retain some of the properties of
ATII cells but do not express some genes such as TTF-1
[30–32]. However, A549 cells have also been reported to
have morphological heterogeneity with various proliferative
activities [33] and are not sensitive to differentiation stimuli,
for example, insulin/dexamethasone (DEX) treatment [34].
Therefore, we first isolated A549 clones and investigated their
gene expression patterns in response to several differentiation
stimuli. We found that A549 clones responded reproducibly
to their stimuli, showing the plasticity in the gene expression
of differentiationmarkers.These findings indicated that A549
clones could be used for an in vitro system to studymolecular
basis of AT cells differentiation.
2. Materials and Methods
2.1. Cell Cultures. A549 cells, a human non-small cell lung
carcinoma cell line, were cultured in Dulbecco’s modified
Eagle’s medium (DMEM, Nissui, Tokyo, Japan) containing
10% fetal bovine serum (FBS, JRH, Bioscience, Lenexa, KS,
USA) at 37∘C in a 5% CO
2
incubator. For maintenance, A549
cells were passaged at 70% confluence, and medium was
changed every 3 days. Hereafter, the original A549 cells are
referred to as parental cells and cloned cells are referred to as
“clones” with individual letters and numbers.
2.2. Characterization of A549 Clones
2.2.1. Single Cell Cloning. A549 clones were isolated by lim-
iting dilution of A549 cells. Briefly, A549 cells were washed
twice with phosphate-buffered saline without calcium and
magnesium [PBS(−)] and dissociated with 0.083% trypsin
(Sigma-Aldrich, Tokyo, Japan) and 0.177mM ethylenedi-
aminetetraacetic acid. Cell numbers were counted with try-
pan blue staining. The cells were seeded at 0.3 or 1 cell/well
into two 96-well plates. When each isolated clone was grown
to 80% confluence, the cells were sequentially transferred into
24-well plates, 6-well plates, and 6 cm dishes.
2.2.2. Morphological Analysis of A549 Clones. Morphology
of A549 cell clones was observed using optical microscope
(CKX41N 31PHP; Olympus Corporation, Tokyo, Japan), and
the images were captured using a digital microscope camera
(DS-Fi2-L3; Nikon, Tokyo, Japan). The thickness of the cells
was analyzed by the mean gray value using ImageJ (National
Institute of Health, Bethesda, MD, USA) as follows: thin,
<5; thick, ≥5. The boundary of cell clusters was evaluated
by smoothness of the cell cluster outline as follows: “clear”
was a smoothly drawn cluster outline and “unclear” was a
hard to draw cluster outline. The cell density was evaluated
by cell numbers within the frame of 100 𝜇m × 100 𝜇m at
70% confluence and evaluated as follows: high, ≥10 cells; low,
<10 cells. The number of cell clusters was observed as the
clustering feature at 1 day after passage using high,≥3; low,<3.
2.2.3. Gene Expression Analysis. The levels of gene expression
were determined by reverse transcription polymerase chain
reaction (RT-PCR). Briefly, total RNA was extracted from
the cells using Tri Reagent (Molecular Research Center,
Cincinnati, OH, USA) following themanufacturer’s protocol.
RT was performed using RNA PCR kit AMV ver. 3.0
(TaKaRa, Shiga, Japan). Synthesized cDNAwas used for PCR
using Go Taq DNA Polymerase (Promega, Madison, WI,
USA). Gene-specific primers and PCR conditions are listed
in Table 1. To detect TTF-1 expression, PCR was performed
by 30 cycles for the initial characterization of clones (Figure 1
and Table 2) and 40 cycles in the other experiments. To detect
SPC expression, the primer set of SPC1 was only used for
the characterization of clones (Figure 1 and Table 2), and the
primer set of SPC2 was used in the other experiments.
2.2.4. Densitometric Analysis. The expression level of each
transcript was normalized by that of 18S ribosomal RNA
(18SrRNA). The images of the electropherogram were cap-
tured using ChemiDoc XRS (BIO-RAD,Hercules, CA, USA),
and volume analysis was performed using Quantity One
(BIO-RAD). The relative ratio was calculated by time 0 as
1. In the case of no expression signals at time 0, the relative
ratio was calculated by the lowest expression level among the
samples as 1.
2.3. Cell Proliferation Assay. The proliferative activity of
the cells was evaluated by counting cell numbers at the
indicated time points using trypan blue and Luna-FL Dual
FluorescenceCell Counter (Logos Biosystems, Inc., Gyunggi-
Do, Korea).
2.4. Induction of Cell Differentiation
2.4.1. Serum-Free System in Culture. Approximately 4.2 × 105
cells of theA549 cell clones, B7 andH12,were seeded in 6-well
plates in DMEM containing 10% FBS. After the cells reached
70% confluence, they were washed twice with PBS(−), and
DMEM without FBS was added. Cell numbers were counted
at 12, 24, 48, 72, 96, and 120 h. For RT-PCR analysis, the cells
were harvested every 24 h.
2.4.2. Stimulation of Epidermal Growth Factor Receptor
(EGFR) Signaling Pathway. B7 andH12 were seeded in 6-well
plates in DMEM containing 10% FBS. After the cells reached
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Table 1: Primers used for RT-PCR.
Gene Primer Annealing (∘C) Cycle Expressed cells
FLK F: 5
󸀠-AAGGCTCAAACCAGACAAGC-3󸀠
R: 5󸀠-TTCCTGCTGGTGGAAAGAAC-3󸀠 58 30 Early mesoderm
PDGFR𝛼 F: 5
󸀠-GGGGAGAGTGAAGTGAGCTG-3󸀠
R: 5󸀠-AGTCTCGGGATCAGTTGTGC-3󸀠 58 30
FOXA2 F: 5
󸀠-CCGGATCGAGGACAAGTGAG-3󸀠
R: 5󸀠-CAACAACAGCAATGGAGGAG-3󸀠 58 30 Endoderm
SOX17 F: 5
󸀠-AAGGGCGAGTCCCGTATCC-3󸀠
R: 5󸀠-TTGTAGTTGGGGTGGTCCTG-3󸀠 58 30
TTF-1 F: 5
󸀠-ACCAGGACACCATGAGGAAC-3󸀠
R: 5󸀠-GCGCCGACAGGTACTTCTG-3󸀠 58 30, 40 Lung progenitor
p63 F: 5
󸀠-TTGCCCCTCCTAGTCATTTG-3󸀠
R: 5󸀠-TACTGTCCGAAACTTGCTGC-3󸀠 58 33 Basal
FOXJ1 F: 5
󸀠-TGGATCACGGACAACTTCTG-3󸀠
R: 5󸀠-AAGTTGCCTTTGAGGGGTTC-3󸀠 58 40 Ciliated
MUC5AC F: 5
󸀠-TACGTGTTCTCCGAGCACTG-3󸀠
R: 5󸀠-GGTTCCACATGAGGACAAGG-3󸀠 58 30 Goblet
CC10 F: 5
󸀠-GTCACACTGGCTCTCTGCTG-3󸀠
R: 5󸀠-GAGCAGTTGGGGATCTTCAG-3󸀠 58 40 Clara
AQP5 F: 5
󸀠-ATCTTCGCCTCCACTGACTC-3󸀠
R: 5󸀠-TTTCTTCTTTTCCCCCTTGG-3󸀠 56 40 Alveolar type I
T1𝛼 F: 5
󸀠-TGGGGTCTTACTAGCCATCG-3󸀠
R: 5󸀠-TAGAGGAGCCAAGTCTGGTG-3󸀠 58 40
CFTR F: 5
󸀠-GCCAGCGTTGTCTCCAAAC-3󸀠
R: 5󸀠-CGATAGAGCGTTCCTCCTTG-3󸀠 58 30
Alveolar type II
SPB F: 5
󸀠-AAGTTCCTGGAGCAGGAGTG-3󸀠
R: 5󸀠-AGAGGAATGGGGAATTGCTG-3󸀠 58 40
SPC1 F: 5
󸀠-TTGGTCCTTCACCTCTGTCC-3󸀠
R: 5󸀠-CTCCCACAATCACCACGAC-3󸀠 58 40
SPC2 F: 5
󸀠-AACGCCTTCTTATCGTGGTG-3󸀠
R: 5󸀠-AAGACTGGGGATGCTCTCTG-3󸀠 58 35
CD133 F: 5
󸀠-GCAGGGATTATTCTATGCTGTG-3󸀠
R: 5󸀠-ACGCCTTGTCCTTGGTAGTG-3󸀠 58 35 Cancer stem
HIF-1𝛼 F: 5
󸀠-TGCTCATCAGTTGCCACTTC-3󸀠
R: 5󸀠-TCTCATTTCCTCATGGTCAC-3󸀠 56 30 Cancer
18SrRNA F: 5
󸀠-TACCTGGTTGATCCTGCCAGTAGGAT-3󸀠
R: 5󸀠-CCCGTCGGCATGTATTAGCTCTAGAA-3󸀠 58 17
70% confluence, they were washed twice with PBS(−),
changed into DMEM without FBS, and human EGF (10, 30,
and 90 ng/mL; Pepro Tec, Rocky Hill, NJ, USA) was added.
For RT-PCR analysis, the cells were harvested every 24 h.
2.4.3. Inhibition of RAS/Mitogen-Activated Protein Kinase
(MAPK) Signaling Pathway. B7 and H12 were seeded in 6-
well plates in DMEM containing 10% FBS. After the cells
reached 70% confluence, they were first treated with the
selective MEK1/2 inhibitor U0126 (3, 10, and 30 𝜇M; Wako,
Osaka, Japan) or the MEK1 inhibitor PD98059 (30, 60, and
90 𝜇M; Wako) in DMEM containing 10% FBS. Cell numbers
were counted at 12, 24, and 48 h. For RT-PCR, the cells were
treated with U0126 (10 and 30 𝜇M) or PD98059 (90𝜇M) and
were harvested at 24 and 48 h.
2.4.4. Combination with MEK Inhibitor and DEX-[8-BR-
cAMP]-IBMX-KGF (DCIK) Treatment. B7 and H12 were
seeded into 6-well plates in DMEM containing 10% FBS.
After the cells reached 70% confluence, they were first
treated with U0126 (30 𝜇M) in DMEM containing 10% FBS.
After 24 h, they were washed twice with PBS(−), and the
mediumwas changed to DMEMwithout FBS ±DEX (50 nM;
Wako), 8-Br-cAMP (0.1mM; Sigma-Aldrich), isobutyl-1-
methylxanthine ([IBMX], 0.1mM; Wako), and keratinocyte
growth factor ([KGF], 50 ng/mL; Wako) for 3 days. DCIK
control was cells without DCIK. The cells were then washed
twice with PBS(−) and cultured in DMEM with or without
FBS for an additional 3 days.
2.5. Statistics. Statistical analysis was performed by Student’s
t-test using Microsoft Excel software. The p value less than
0.05 indicates being statistically significant.
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Day 1 Day 2
Day 3 Day 4
(a)
d3d1 d2 N2N1d4 P
FLK1
PDGFR𝛼
SOX17
FOXA2
TTF-1
p63
FOXJ1
MUC5AC
CC10
T1𝛼
AQP5
SPC
CFTR
CD133
18SrRNA
(b)
FLK1
PDGFR𝛼
SOX17
FOXA2
TTF-1
p63
FOXJ1
MUC5AC
CC10
T1𝛼
AQP5
SPC
CFTR
CD133
18SrRNA
621 43 5 117 8 109 12 N2N1 P
(c)
H10 G8
H12 B7
G9
(d)
Figure 1: Characterization of A549 cells. (a) Representative morphology of A549 parental cells during growing phase. Cells were monitored
for 4 days after passage. Scale bars: 100𝜇m. (b) Gene expression of A549 parental cells shown in (a). 18SrRNAwas used as the internal control.
d1 to d4: day 1–day 4 shown in (a), N1: negative control of PCR products without RT reaction, N2: negative control with distilled water, and
P: positive control with sequenced PCR products in plasmid. (c) Gene expression of A549 clones. The number indicated the group of clones
as shown in Table 3. N1, N2, and P are the same symbols as in (b). (d) Representative morphology of A549 clones at 70% confluence. A549
clones were classified into five groups as shown in Table 4 and selected the representative clones. Scale bars: 100𝜇m.
3. Results
3.1. Characterization of A549 Parental Cells and Clones. To
analyze the characteristics of A549 parental cells, we first
observed their morphology in the growing phase for 4
days after seeding. As shown in Figure 1(a), we detected
several variations of morphologies in A549 parental cells. We
concurrently examined the expression patterns of 14 differ-
entiation marker genes using one of the paired experimental
sets (Figure 1(b)) and summarized the results in Table 2.
We found that the forkhead box genes, that is, FOXJ1 and
FOXA2, transformation-related protein 63 (p63), mucin-5AC
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(MUC5AC) which is a goblet cell marker, and SPC were
constantly expressed at the similar levels throughout the
culture period. These genes are the specific markers for
endoderm cells, basal cells, ciliated cells, goblet cells, and
ATII cells, respectively. Aquaporin 5 (AQP5), a marker for
ATI cells, was expressed on day 1 only, and Clara cells 10 kDa
secretory protein (CC10), a marker for Clara cells, was slightly
expressed on days 1–3 during the growing phase. Expression
of Prominin-1 (CD133), a marker for cancer stem cells, was
enhanced with the days of culture. To obtain clones from
A549 parental cells, we next performed limiting dilution and
46 clones were isolated. We classified these clones into 12
groups according to morphological differences. The average
number of days to obtain a confluent monolayer of each
clone was 3.7 except for clone G8 cells (14 days). Other
morphological characteristics of each clone, including cell
thickness, appearance of cell cluster boundaries, cell density,
and clustering, were observed and are shown in Table 3. We
further examined the expression profiles of marker genes
using representative clones from each group (Figure 1(c)).
Expressions of FLK1, SOX17, TTF-1, T1𝛼, and CFTR were not
detected in all clones. In contrast, all clones expressed p63.
Clone G8 in group 4 uniquely expressed the gene encoding
platelet-derived growth factor receptor 𝛼 (PDGFR𝛼), but did
not express FOXA2, MUC5AC, or CD133. FOXJ1 was not
expressed in groups 3, 4, and 5. CC10 was slightly expressed
only in groups 1 and 2. AQP5 was expressed only in groups
2, 5, 7, 10, and 11, and SPC was detected in all of them except
group 1.
Based on these data, we further classified them into
five classes, as shown in Table 4. The representative cell
morphology was demonstrated in Figure 1(d). H10 in class 1
was spindle shaped with a slim nucleus. MUC5AC, a goblet
cell marker, was highly expressed, but SPC and AQP5 were
not detected in H10. G8, in class 2, grew slowly and showed
a piled-up growth. SPC, p63, and PDGFR𝛼 were expressed,
but FOXA2, MUC5AC, and CD133 were not detected. H12,
in class 3, had a tendency to cluster and the outline of the
cell cluster boundary was bright and clearly visible. The cells
expressed both AQP5 and SPC, which are typical markers
for ATI cells and ATII cells, respectively. B7, in class 4, was
polygonal shaped with high cell density but the outline of the
cell boundaries was unclear. B7 expressed SPC, but notAQP5.
G9 in class 5 shared similar gene expression patterns with B7
but showed invadopodia-like structures.
The gene expression pattern shown in Table 4 suggested
that B7 had ATII-like characteristics, and H12 had both ATI-
like and ATII-like characteristics. These clones were used
for further analyses as potential representatives of ATII and
ATI/ATII, respectively.
3.2. Effects of Serum Depletion on B7 and H12 Clones.
Proliferation and differentiation are reciprocally and tightly
regulated [35]. Because A549 cells are derived from lung
adenocarcinomas, it was generally thought that the cells
reduced serum dependency and acquired the increase in
autonomous growth.Thereby, we initially examined the effect
of serum depletion on their proliferation (Figure 2(a)). Both
B7 and H12 increased their cell numbers in the culture
medium with serum until 72 h. However, cell proliferation
was suppressed from 48 h in the serum-free medium. After
72 h, cell numbers started to decrease in both culture con-
ditions. Next, we examined the effects of serum depletion
on the gene expression of SPC, AQP5, and also hypoxia-
inducible factor-1𝛼 (HIF-1𝛼) which regulates the phenotypes
of cancer cells including their progressive proliferation [36–
38] (Figures 2(b) and 2(c)). In B7, significant enhancement of
SPC expression was observed from 48 h by serum depletion
compared with control (Figure 2(b)). At 120 h, the expression
level was upregulated 2.9-fold compared with that at time
0. In contrast, AQP5 was induced significantly at 24 h and
the expression level was maintained until 120 h by serum
depletion.The expression level ofHIF-1𝛼was not significantly
altered.
On the other hand, in H12, SPC expression was enhanced
from 24 h by the serum depletion when compared to the
control (Figure 2(c)). The maximum expression level was
observed at 72 h as a 1.7-fold increase compared with that
at time 0. However, in contrast to B7, the expression level
started to decrease from 96 h in conditions with or without
serum. AQP5 expression was enhanced in a time-dependent
manner by serum depletion, and the maximum expression
level was 2.8-fold at 120 h compared with that at time 0.HIF-
1𝛼 expression was not significantly altered. All of these results
indicate that the response to serum depletion was different
between B7 and H12.
3.3. Effects of EGF Treatment on Gene Expression in B7 and
H12 Clones. Because serum contains growth factors and
A549 cells have been reported to undergoEGFR amplification
[29], we hypothesized that the effects of serum depletion
could be because of the absence of EGF in the serum. To
confirm this possibility, we cultured B7 and H12 in the
serum-free medium with EGF (10, 30, and 90 ng/mL). In B7,
SPC expression was enhanced from 24 h by serum depletion
(Figure 3(a)). Ten and 30 ng/mL of EGF treatment did not
affect SPC expression. A minor suppression of SPC was
observed by 90 ng/mL of EGF treatment. In contrast, AQP5
expression was induced from 24 h by serum depletion. By the
addition of EGF, the induction ofAQP5was delayed in a dose-
dependent manner. In H12, the enhancement of both SPC
and AQP5 expressions by serum depletion was not affected
by EGF treatment (Figure 3(b)). These results indicated that
EGF in serum-containing medium had little effect on the
alveolus-specific gene expression.
3.4. Effects of MEK Inhibitors on Gene Expression in B7 and
H12 Clones. A549 cells have been demonstrated to have
the K-RAS mutation (G12S) and show activation of MAPK
signaling [27, 28]. To examine whether serum depletion
effects could be replaced by inhibition of MAPK signaling,
we treated B7 and H12 with U0126 and PD98059. We first
confirmed the effects on cell proliferation of both clones
treated with U0126 (3, 10, and 30 𝜇M) or PD98059 (30,
60, and 90𝜇M), respectively (Figure 4(a)). In both B7 and
H12, cell proliferation was suppressed by both U0126 and
PD98059 in a dose-dependent manner. The most effective
dose was 30 𝜇M of U0126 and 90 𝜇M of PD98059. Although
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Figure 2: Effects of serum depletion on cell characteristics of A549 clones. (a) Growth curve of B7 (left) and H12 (right). Black: cultured with
serum, red: cultured without serum. (b) and (c) Expression and quantitative analyses of SPC, AQP5, andHIF-1𝛼mRNA in B7 cells (b) and in
H12 cells (c). (Upper panel) representative RT-PCR results. N1: negative control without RT reaction, N2: negative control with distilled water,
and P: positive control with sequenced PCRproducts in plasmid. (Lower three panels) quantitative analysis of gene expression. Black: cultured
with serum, red: cultured without serum. Experiments were independently performed in triplicate. ∗𝑝 < 0.05; ∗∗𝑝 < 0.01; ∗∗∗𝑝 < 0.001.
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Figure 3: Effects of EGF treatment on gene expression in B7 and H12 clones. (a) and (b) Expression and quantitative analyses of SPC and
AQP5 mRNA in (a) B7 and in (b) H12. (Upper panel) representative RT-PCR results. Serum +: cultured with serum, −: cultured without
serum, N: negative control without RT reaction, and P: positive control. (Lower panel) quantitative analyses of gene expression. Black: serum,
red: serum-free, green: serum-free + EGF 10 ng/mL, light blue: serum free + EGF 30 ng/mL, and purple: serum-free + EGF 90 ng/mL. All
data were independently obtained twice.
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these concentrations seemed to be relatively high compared
to the dosages used in the previous studies to inhibit ERK
phosphorylation (e.g., 10 𝜇MofU0126 and 25𝜇MofPD98059
[39, 40]), we did not observe increasing numbers of floating
cells dependent on the culturing time (data not shown).
When we harvested the attached cells, the morphology was
the same as that of healthy cells, and the viability of collected
cells was more than 90% (data not shown). Therefore, we
assessed both concentrations of inhibitors were not toxic. A
slight difference in growth response to MEK inhibitor was
observed between B7 and H12. B7 was much more sensitive
to both inhibitors than H12 and showed earlier suppression
of cell proliferation than H12.
Next, we examined the effects of the MEK inhibitors
on gene expression in B7 and H12. In B7, SPC expres-
sion was transiently upregulated 1.9-fold at 24 h by U0126
treatment; however, it was decreased by PD98059 treatment
when compared with the control (Figure 4(b)). Although
TTF-1 expression was not detected by 30 cycles, it could
be detected by 40 cycles. Under this PCR condition, TTF-1
expression was upregulated 1.2-fold after U0126 treatment
and 1.1-fold after 24 h treatment with PD98059. At 48 h,TTF-1
expression was decreased under all conditions except serum
depletion. The effects of the MEK inhibitor on both AQP5
and SPB expression were varied. On the other hand, in
H12, SPC expression was transiently upregulated 1.7-fold at
24 h after U0126 treatment, but not after PD98059 treatment
(Figure 4(c)). TTF-1 expression was transiently upregulated
1.5-fold at 24 h after U0126 treatment and 1.4-fold after
PD98059 treatment. Expression levels of AQP5 and SPBwere
not altered by U0126 and PD98059 treatment.
3.5. Effects of DCIK Treatment on B7 and H12 Clones.
Previous studies reported that TTF-1 can promote SPC and
SPB expression [18–20]. Although SPC and TTF-1 expression
was enhanced afterU0126 treatmentwas transiently observed
in some cases, it was not reproducible in our experiments.
Recently, DCIK treatment has been reported to promote
differentiation of progenitor cells induced from mouse ESCs
and human iPSCs into ATII cells [41, 42]. Furthermore, the
tissue-derived ATII cells could maintain their characteristics
in vitro with DCI treatment [43, 44]; in addition, following
DCI removal, they could enhance the expression for ATI cell
markers [45]. To test whether A549 clones respond to the
culture conditions with DCIK, we next examined the effects
ofDCIK addition on the expression ofATII cellmarker genes,
following MEK inhibitor treatment. As shown in Figure 5(a),
we first cultured B7 and H12 cells at 70% confluence with
30 𝜇M of U0126 for 24 h. After that, we changed the medium
without DCIK (DCIK control) or with DCIK (DCIK) in
the serum-free medium and continued to culture for 72 h
(total culture time was 96 h). After DCIK treatment, we
exchanged the culturemedium to removeDCIK and cultured
with serum (DCIK + serum) or without serum (DCIK +
serum free) for 72 h. The morphology of B7 was significantly
changed by DCIK treatment (Figure 5(b)). The shape of B7
became flat and spindle-like after 48 h, and the outline of
cell border became clearer. These elongated cells increased
in a time-dependent manner, but the clear outline of cells
was maintained at the similar level during the entire culture
period.
We next examined the effects of combined treatment
with MEK inhibitor and DCIK on the gene expression in B7
(Figure 5(c)). When compared with time 0, SPC expression
was enhanced duringU0126 treatment until 24 h. AfterDCIK
addition, SPC expression was decreased by 48 h and then
increased in a time-dependent manner until 96 h. However,
these changeswere observed in the samemanner in theDCIK
control. In contrast, at 72 h, AQP5 was suppressed 0.5-fold
in DCIK, when compared with the DCIK control. TTF-1
expression was significantly increased up to 1.6-fold after
DCIK treatment when compared with the DCIK control.
SPB was also enhanced in a time-dependent manner from
48 h and reached a 2.1-fold upregulation at 96 h. After DCIK
removal, SPC expression was decreased by 120 h and then
increased in medium with and without serum in a time-
dependent manner. AQP5 was expressed only under serum-
free conditions. However, TTF-1 and SPB expression levels
were decreased by DCIK removal.
We also performed the same experiments with H12.
Morphological changes were not observed in H12 after DCIK
treatment (Figure 5(d)), but cells were more clustered after
48 h. We next examined the effects of combined MEK
inhibitor-DCIK treatment on the gene expression in H12
(Figure 5(e)). SPC expression was enhanced during U0126
treatment until 24 h. After DCIK addition, SPC expres-
sion was decreased by 48 h and then increased in a time-
dependentmanner until 96 h.AQP5was suppressed in DCIK
at 48 h and remained at 0.7-fold after 72 h. TTF-1 expression
was upregulated 1.3-fold at 48 h and remained at that level
until 96 h. SPB expression was significantly increased by 48 h
showing, up to 4.6-fold upregulation at 72 h and remaining
at that level until 96 h. After DCIK removal, SPC expression
was decreased by 120 h and then increased in medium with
and without serum in a time-dependent manner. AQP5 was
increased in a time-dependent manner in serum-free culture
medium. TTF-1 decreased transiently at 120 h but recovered
to the original expression level. SPB decreased but SPC
increased in a time-dependent manner after DCIK removal.
4. Discussion
In this study, we tried to establish a simple and reproducible
in vitro system that can be used to analyze the molecular
mechanisms of lung alveolar epithelial cell differentiation.
We isolated A549 clones and characterized them by pheno-
typic screening using their morphology and gene expression
patterns of markers (Tables 2–4). According to the major
expression patterns of alveolar cell markers [30, 46], two
A549 clones, B7 and H12, were further analyzed as tentative
representatives for ATII and ATI/II cells.
We examinedwhether these clones showed any responses
to the differentiation stimuli by inducing several culture con-
ditions with or without serum, DCIK, and MAPK inhibitors.
Both B7 and H12 had unique responses to those stimuli,
reflecting the characteristics of ATII and ATI/II cells, and
these responses were stably and reproducibly observed until
passage 122 and passage 120, respectively (data not shown).
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Figure 4: Continued.
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Figure 4: Effects of MEK inhibitors on gene expression in B7 and H12 clones. (a) Growth curve of B7 and H12 in serum-present medium
treatedwithU0126 and PD98059, respectively. U0126were treatedwith 3 𝜇M(red), 10𝜇M(light blue), and 30 𝜇M(purple), and PD98059were
treated with 30 𝜇M (red), 60𝜇M (light blue), and 90𝜇M (purple) for the indicated time. Black indicted no treatment with MEK inhibitors.
(b) and (c) mRNA expression and quantitative analysis of SPC, AQP5, TTF-1, and SPB by RT-PCR in B7 (b) and in H12 (c). Each data
was independently obtained twice. (Upper panel) representative RT-PCR results. N: negative control, P: positive control. (Lower panel)
quantitative analyses of gene expression. Black: cultured with serum, red: cultured without serum, green: PD98059 90𝜇M, light blue: U0126
10𝜇M, and purple: U0126 30 𝜇M.
The finding that serum-free condition could induce the
gene expression of alveolar epithelial differentiation markers
in A549 clones is consistent with those of the previous study
[47].
Since cell growth and differentiation are reciprocally and
tightly regulated [35], we characterized the growth rate with
and without serum. We observed that A549 cells were highly
proliferative in medium with serum, but serum depletion
decreased the growth rate and reciprocally increased the
expression of differentiation marker genes. In addition, both
SPC and AQP5 proteins were not detectable by western
blot analyses in serum depletion system (data not shown).
Therefore, the cells can be primed but not fully differentiated
in the present condition, suggesting that additional signals
or environmental condition might be required to induce the
protein expression.
Because K-RASmutation (G12S) and EGFR amplification
were detected in A549 cells, the effects of serum depletion
were first considered to be related to the MAPK signaling
cascade which is also known to play an important role in
proliferation of cancer [48]. We found that the proliferation
of A549 clones could be suppressed by the MEK inhibitor
U0126 and showed an enhancement in the expression of
the differentiationmarkers, SPC andTTF-1 (Figure 4).U0126,
a MEK1/2 inhibitor [49], caused an enhancement in the
SPC expression up to 24 h and then caused a reduction or
maintenance up to 48 h; however, it did not affect AQP5
expression. PD98059, a MEK1 inhibitor [50], did not affect
either SPC or AQP5 expression. This suggests that RAS-
MAPK signalsmight control the switch between proliferation
and differentiation in A549 clones. The differential effects
of these inhibitors on marker gene expression might be
because of different target molecules, but this remains to be
determined.
Second, serum contains a variety of factors, including
growth factors such as EGF. Lauand et al. demonstrated
that A549 cells amplified EGFR without phosphorylation,
and EGF stimulation could activate actin filament organiza-
tion and cell motility rather than inducing proliferation in
A549 cells [51]. However, we observed that EGF had little
effect on the expression of differentiation markers (Figure 3).
Therefore, it is possible that other ligands in serum, such
as tumor necrosis factor-𝛼, amphiregulin, and heparin-
binding EGF-like growth factor [52–55] could activate EGFR-
mediated signals. Further analysis is required to determine
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Figure 5: Effects of DCIK treatment following U0126 treatment. (a) Experimental design. B7 and H12 were treated with DCIK for 3 days
following U0126 30𝜇M treatment for 24 h. After DCIK removal, B7 and H12 were cultured with serum or without serum for 3 days. (b)
Morphological change of B7 treated without DCIK (control) and with DCIK (DCIK) at every 24 h for 3 days following U0126 treatment
for 24 h. Scale bar: 100𝜇m. (c) Expression and quantitative analysis of SPC, AQP5, TTF-1, and SPB mRNAs in B7. (Upper panel) RT-PCR
results. (Lower four panels) quantitative analyses of gene expression. Black: cultured with serum, red: cultured without serum, green: cultured
withoutDCIK followingU0126 treatment for 24 h, light blue: culturedwithDCIK followingU0126 treatment for 24 h and culturedwith serum
following DCIK treatment, and purple: cultured without serum following DCIK treatment. (d) Morphological change of H12 treated without
DCIK (control) and with DCIK (DCIK) at every 24 h for 3 days following U0126 treatment for 24 h. Scale bar: 100𝜇m. (e) Expression and
quantitative analysis of SPC, AQP5, TTF-1, and SPBmRNAs in H12. (Upper panel) RT-PCR results. (Lower four panels) quantitative analyses
of gene expression. Indications were the same as in (c). All data were independently obtained twice.
16 Stem Cells International
the mechanism of the enhancement in differentiationmarker
gene expression under serum-free condition.
To induce cell differentiation, the control of energy
metabolism is another important issue to be discussed. The
energy metabolism in A549 cells is regulated by theWarburg
effect [56]. Aerobic glycolysis is dominant andmitochondrial
oxidative phosphorylation is decreased.The switch in energy
metabolism from glycolysis to mitochondrial oxidative phos-
phorylation has been demonstrated to induce differentiation
in cancer cells [57]. That prompted us to examine the effects
of glycolysis and/or pyruvate dehydrogenase kinase- (PDK-)
inhibitors to increase the flow of carbon metabolites into
tricarboxylic acid cycle and switch the differentiation cue.We
examined the effects of glycolysis by culture in the specific
medium (depleted with L-glutamine, glucose, and sodium
pyruvate), the inhibitors of both pyruvate dehydrogenase
kinase and lactate dehydrogenase combined with U0126
on the gene expression levels of differentiation markers.
However, we did not detect any induction or enhancement
in gene expression as a result of these treatments (data not
shown), suggesting that in our experimental condition, at
least in part, glucose metabolism did not have a major role
in the A549 clones.
Recently, several reports have studied the suitable culture
conditions to maintain ATII function and induce ATI dif-
ferentiation [41–45]. DCI treatment in vitro could maintain
and enhanceATII characteristics of natural ATII cells isolated
from lung in human fetuses and adults [43, 44]. Furthermore,
KGF treatment could increase surfactant protein gene expres-
sion and decrease AQP5 expression [58–60]. Using mouse
ESCs and human iPSCs, it has also been reported that KGF
combined with DCI treatment leads to the maturation of
ATII-like cells from the progenitor cells [41, 42, 61]. Since
mouse epiblast stem cells and human iPSCs have been shown
to have a similar energy metabolism to cancer cells [62],
we used the combination of U0126 and DCIK to suppress
cell proliferation and examined the cell morphology and
gene expression of alveolar differentiationmarkers (Figure 5).
This treatment induced a morphological change (flat and
spindle shape) in B7, and increased cell-clustering in H12,
respectively. SPC was not significantly increased by DCIK
treatment, but SPB and TTF-1 were significantly enhanced.
AQP5 expression, however, was decreased in both clones.
These findings suggested that the expression of ATII-marker
genes was enhanced by DCIK treatment. The morphological
change in B7 which we observed was slightly similar to
the epithelial mesenchymal transition; however, epithelial
markers SPB and SPC were detected. Further analysis is
required for better understanding the meaning of morpho-
logical change induced by DCIK treatment. In addition,
ATII-like cells could be differentiated from the isolated ATII
cells of human fetal lung, which were maintained in a DCI-
added medium, into ATI-like cells, by the removal of DCI
[45]. In our system using A549 clones, DCIK removal did
not affect either AQP5 or SPC expression but decreased SPB
expression. These data suggest that A549 clones require the
additional cues for ATI induction.
For the in vivo events following lung injury,ATII cells pro-
liferate and spread, and their daughter cells could differentiate
into ATI cells [21–24]. An in vitro study demonstrated that
siRNA of transforming growth factor-𝛽 (TGF-𝛽) and recom-
binant human bone morphogenetic protein- (rhBMP-) 4
could upregulate expression of ATII markers, whereas siRNA
of BMP receptors and rhTGF-𝛽 upregulated expression of
ATImarkers inmouseATII cells [63]. Additionally, ATII cells
treated with insulin-like growth factor-I (IGF-I) differentiate
into ATI-like cells by activation of Wnt5a in rat ATII cells
[64]. These findings indicated that cytokine signals might
play the key roles in both genetic and epigenetic programs
during lung development.
Finally, we obtained an interesting finding about genetic
background of B7 and H12 clones by analyzing the cell
authentication. Both B7 and H12 maintain A549 signature,
except Y chromosome-loss in H12 (data not shown). Y
chromosome instability has been reported in some of human
cancer, and it is thought that Y chromosome loss or gain is
related with progression of malignancy [65]. However, the
biological meaning of Y chromosome instability in tumor
progression is still unclear. Interestingly, the introduction
of Y chromosome into the human prostate cancer cell
line, PC-3, suppressed tumor formation [66], and loss of
Yp11.2 containing TSPY gene shows strong correlation with
tumorigenesis in prostate cancer [67]. And a recent study
reported the loss of Y chromosome in the elderly peripheral
blood is associated with shorter cancer survival and higher
risk of cancer incidence [68]. Since tumor cells have plasticity
and phenotypic heterogeneity [69], Y chromosome-loss can
be a cause of the phenotypic difference between B7 and H12.
Further detailed analyses of Y chromosome-loss, epigenetic
status, and transcriptome analysis in H12 are required for
better understanding the characteristics of the clone H12 and
the mechanism of alveolar differentiation.
Taken together, we summarized our findings in Figure 6
as an in vitro A549 model compared with an in vivo model
that has been recently reported [25]. During lung alveolar
development, the bipotent progenitor cells differentiate into
ATI and ATII cells. When alveoli are injured or damaged in
adult, ATII cells can differentiate into ATI cells and maintain
the supply of ATII cells by self-renewal to keep alveolar
homeostasis and restore the tissue defects [21–26]. However,
when ATII cells acquired a K-RAS mutation and/or EGFR
mutation, they could be transformed into cancer cells [70, 71].
In an A549 model, A549 has been demonstrated to have
K-RASmutation (G12S) and EGFR amplification [27–29] and
lose some of the characteristics of ATII cells [31, 32]. In
our study, we found that A549 clone B7 has characteristics
of ATII cells, and H12 has characteristics of both ATI and
ATII cells based on the expression of differentiation marker
genes. We also observed that ATII-like characteristics could
be enhanced or recovered, in both B7 and H12, under the
culture condition with U0126 followed by DCIK treatment.
Further analyses are required to understand the detailed
regulatory mechanisms of ATI and ATII marker gene expres-
sion and find out further effective differentiation system
using these clones. Our findings suggested that A549 clones
would provide a simple and easy in vitro model system as
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Figure 6: In vivo lung alveoli and in vitro A549 model. (a) In vivomodel. Bipotent progenitor cells differentiate into ATI cells and ATII cells.
ATII cells have stem cell-like functions, which are able to differentiate into ATI cells by injury and to maintain themselves by self-renewal.
When EGFR and/or K-RAS are mutated, they may cause transformation of ATII cells. (b) In vitro A549 model proposed from the current
study. A549 has been demonstrated to have K-RAS mutation (G12S) and EGFR amplification. In A549 clones, B7 have characters of ATII
cell, and H12 have characters of both ATI and ATII cells. Both B7 and H12 can be enhanced the cell-type-specific markers of ATII-like cells
by treatment of U0126 + DCIK. Injury, TGF-𝛽, and IGF-1 may regulate differentiation from ATII-like cells into ATI-like cells. Black arrow:
direction of differentiation; red arrow: experimental stimuli; dotted arrow: hypothesis. Yellow oval: nuclei of normal cells; black oval: nuclei
of cancer cells; gray oval: nuclei of differentiated clones.
the potential representatives of bipotent ATI/II and ATII cells
andwould elucidate themolecular basis for ATII self-renewal
and differentiation from ATII cells into ATI cells.
5. Conclusions
In this study, we isolated A549 clones and characterized their
distinct characteristics in morphology and gene expression
patterns. Among them, we found that two A549 clones, B7
and H12, have ATII cell- and ATI/ATII cell-like characteris-
tics, and they were responsive to the serum depleted stimuli,
suggesting that they have the plasticity in gene expression
of alveolar differentiation markers. These A549 clones could
become the sources of model system to study the molecular
basis of regulation for ATII differentiation.
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